Acquired by ArchiMed Group in July 2022
NTUS - Natus Medical Incorporated
NASDAQ
->
Healthcare
->
Medical Devices
Pleasanton,
United States
Type: Equity
NTUS price evolution
NTUS
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $84.28 | $75.59 | $68.78 | $62.49 |
| Short term investments | ||||
| Net receivables | $103.71 | $111.76 | $97.37 | $92.79 |
| Inventory | $72.24 | $67.75 | $71.55 | $68.35 |
| Total current assets | $286.77 | $277.29 | $261.67 | $245.7 |
| Long term investments | ||||
| Property, plant & equipment | $29.42 | $31.07 | $32.78 | $34.5 |
| Goodwill & intangible assets | $208.12 | $214.17 | $222.9 | $230.54 |
| Total noncurrent assets | $281.31 | $287 | $299.58 | $310.52 |
| Total investments | ||||
| Total assets | $568.08 | $564.29 | $561.25 | $556.22 |
| Current liabilities | ||||
| Accounts payable | $34.34 | $36.41 | $28.32 | $26.89 |
| Deferred revenue | $26.85 | $25.1 | $25.74 | $24.46 |
| Short long term debt | $4.48 | $4.96 | $5.17 | $5.85 |
| Total current liabilities | $112.86 | $114.6 | $103.8 | $102.46 |
| Long term debt | $5.75 | $6.57 | $7.37 | $8.06 |
| Total noncurrent liabilities | $24.33 | $24.94 | $34.93 | $35.93 |
| Total debt | $10.24 | $11.53 | $12.54 | $13.91 |
| Total liabilities | $137.19 | $139.54 | $138.73 | $138.39 |
| Shareholders' equity | ||||
| Retained earnings | $86.39 | $84.49 | $82.74 | $77.17 |
| Other shareholder equity | -$14.81 | -$13.47 | -$10.68 | -$7.16 |
| Total shareholder equity | $430.89 | $424.75 | $422.52 | $417.83 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $75.59 | $82.08 | $63.3 | $56.37 |
| Short term investments | ||||
| Net receivables | $111.76 | $93.13 | $115.89 | $127.04 |
| Inventory | $67.75 | $75.65 | $71.37 | $79.74 |
| Total current assets | $277.29 | $271.7 | $269.75 | $285.77 |
| Long term investments | ||||
| Property, plant & equipment | $31.07 | $36.19 | $39.75 | $22.91 |
| Goodwill & intangible assets | $214.17 | $244.04 | $261.17 | $287.1 |
| Total noncurrent assets | $287 | $328.69 | $352.78 | $352.37 |
| Total investments | ||||
| Total assets | $564.29 | $600.39 | $622.53 | $638.14 |
| Current liabilities | ||||
| Accounts payable | $36.41 | $23.43 | $27.25 | $28.8 |
| Deferred revenue | $25.1 | $21.31 | $20.25 | $17.07 |
| Short long term debt | $4.96 | $56.78 | $40.87 | $35 |
| Total current liabilities | $114.6 | $145.75 | $142.82 | $133.45 |
| Long term debt | $6.57 | $14.8 | $31.72 | $69.47 |
| Total noncurrent liabilities | $24.94 | $43.55 | $63.58 | $106.25 |
| Total debt | $11.53 | $71.58 | $72.59 | $104.47 |
| Total liabilities | $139.54 | $189.3 | $206.4 | $239.7 |
| Shareholders' equity | ||||
| Retained earnings | $84.49 | $71.31 | $87.92 | $102.26 |
| Other shareholder equity | -$13.47 | -$3.04 | -$16.27 | -$38.03 |
| Total shareholder equity | $424.75 | $411.09 | $416.12 | $398.44 |
| (in millions $) | 1 May 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $128.66 | $113.88 | $115.98 | |
| Cost of revenue | $55.61 | $46.13 | $49.58 | |
| Gross Profit | $73.04 | $67.75 | $66.4 | |
| Operating activities | ||||
| Research & development | $13.75 | $14.27 | $14.25 | |
| Selling, general & administrative | $41.73 | $41.11 | $42.1 | |
| Total operating expenses | $68.34 | $59.2 | $60.39 | |
| Operating income | $4.7 | $8.54 | $6.01 | |
| Income from continuing operations | ||||
| EBIT | $3.63 | $7.5 | $5.36 | |
| Income tax expense | $1.89 | $1.92 | $1.9 | |
| Interest expense | ||||
| Net income | ||||
| Net income | $1.74 | $5.57 | $3.46 | |
| Income (for common shares) | $1.74 | $5.57 | $3.46 | |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $473.44 | $415.68 | $495.18 | $530.89 |
| Cost of revenue | $199.76 | $199.15 | $203.47 | $226.88 |
| Gross Profit | $273.68 | $216.53 | $291.71 | $304.01 |
| Operating activities | ||||
| Research & development | $56.31 | $61.3 | $58.73 | $61.48 |
| Selling, general & administrative | $168.77 | $156.4 | $188.76 | $207.28 |
| Total operating expenses | $249.9 | $236.72 | $307.37 | $328.58 |
| Operating income | $23.78 | -$20.19 | -$15.67 | -$24.56 |
| Income from continuing operations | ||||
| EBIT | $19.36 | -$22.07 | -$21.26 | -$32.26 |
| Income tax expense | $6.18 | -$5.45 | -$5.59 | -$9.32 |
| Interest expense | ||||
| Net income | ||||
| Net income | $13.18 | -$16.61 | -$15.67 | -$22.93 |
| Income (for common shares) | $13.18 | -$16.61 | -$15.67 | -$22.93 |
| (in millions $) | 31 Mar 2022 | 31 Dec 2021 | 30 Sep 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | $1.9 | $1.74 | $5.57 | $3.46 |
| Operating activities | ||||
| Depreciation | $6.67 | $6.75 | $6.89 | $7.19 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.62 | $5.89 | $2.65 | $2.51 |
| Total cash flows from operations | $8.9 | $12.78 | $7.12 | $19.39 |
| Investing activities | ||||
| Capital expenditures | -$1.06 | -$0.67 | $1.69 | -$1.24 |
| Investments | -$0.57 | -$1 | ||
| Total cash flows from investing | -$1.63 | -$0.67 | $1.69 | -$2.24 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $4.19 | $0.24 | $0.61 | |
| Net borrowings | -$0.45 | -$0.08 | -$0.11 | -$37.09 |
| Total cash flows from financing | $2.52 | -$2.69 | -$0.12 | -$36.57 |
| Effect of exchange rate | -$1.09 | -$2.6 | -$2.4 | $1.36 |
| Change in cash and equivalents | $8.69 | $6.82 | $6.29 | -$18.05 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | $13.18 | -$16.61 | -$15.67 | -$22.93 |
| Operating activities | ||||
| Depreciation | $28.09 | $29.47 | $30.72 | $33.86 |
| Business acquisitions & disposals | -$2 | $0.15 | ||
| Stock-based compensation | $14.16 | $9.57 | $8.35 | $17.05 |
| Total cash flows from operations | $63.99 | $34.43 | $60.06 | $33.02 |
| Investing activities | ||||
| Capital expenditures | -$0.95 | -$8.61 | -$5.33 | -$7.88 |
| Investments | -$1 | -$2 | ||
| Total cash flows from investing | -$1.95 | -$12.61 | -$5.34 | -$8.39 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.85 | -$9.18 | $3.63 | $5.82 |
| Net borrowings | -$57.41 | $1.47 | -$50.48 | -$50 |
| Total cash flows from financing | -$60.66 | -$10.88 | -$48.53 | -$49.51 |
| Effect of exchange rate | -$7.87 | $7.84 | $0.73 | -$7.7 |
| Change in cash and equivalents | -$6.49 | $18.79 | $6.92 | -$32.58 |
News
|
Has Natus Medical (NTUS) Outpaced Other Medical Stocks This Year?
Zacks via Yahoo Finance
29 Apr 2022
|
|
Deal Watch: Skadden, Wilson Sonsini, Simpson and Davis Polk Usher in Musk Era at Twitter | The...
Law.com
26 Apr 2022
|
|
Merger Arbitrage Mondays - Blackstone Acquires American Campus Communities (NYSE:ACC)
Seeking Alpha
25 Apr 2022
|
|
68 Biggest Movers From Yesterday
Benzinga
19 Apr 2022
|
|
Natus Medical to Be Acquired By ArchiMed in $1.2 Billion Deal By Investing.com
Investing.com
19 Apr 2022
|
|
34 Stocks Moving In Monday's Mid-Day Session
Benzinga
18 Apr 2022
|
|
Midday Stock Movers: Casa Systems, BofA, Twitter
Investing.com
18 Apr 2022
|
|
Midday Stock Movers: Casa Systems, BofA, Twitter
Investing.com
18 Apr 2022
|
|
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.11%
Investing.com
18 Apr 2022
|
|
Is Natus Medical (NTUS) a Worthy Stock for Value Investors?
Zacks via Yahoo Finance
7 Apr 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 34.58M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 12.89 |
| Cash/Share | 2.44 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.54 |
| Quick ratio | 1.90 |